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BACKGROUND: Breast-conserving therapy (BCT) has emerged as the preferred treatment for most women with early
stage breast cancer. However, there is concern for underuse in the elderly, with previously documented low rates of
BCT and large variations in practice patterns. The authors’ purpose was to examine patterns and correlates of BCT
for breast cancer in the elderly US population. METHODS: The primary outcome was receipt of BCT. The 2003 to
2004 Medicare inpatient, outpatient, and carrier files were used to identify incident breast cancer patients and the
American Medical Association to ascertain surgeon information. The primary independent variables were US state
where treatment was performed along with patient and surgeon sociodemographic information. Multivariate logistic
regression was used for the analyses. RESULTS: BCT was performed in 81.8% of patients (N ¼ 20,032). Variation in
use of BCT across states was low, ranging from 74.2% in Utah to 84.0% in New Mexico. Several factors were
significantly associated with low use of BCT: advanced patient age (>85 vs <70 years: odds ratio [OR], 0.50; 95%
confidence interval [CI], 0.42-0.59); comorbidities (>3 vs 3: OR, 0.26; 95% CI, 0.24-0.28), and low socioeconomic
status (SES) (lowest quintile vs highest quintile SES: OR, 0.60; 95% CI, 0.52-0.68). Variation in use of BCT by surgeon
was low, although female surgeons aged 40 to 49 years and 60 years had significantly higher use compared with
younger men. CONCLUSIONS: BCT has become the primary management among elderly breast cancer patients.
Despite earlier studies to the contrary, there is now little variation in BCT use among Medicare patients. Cancer
2011;117:698–704. VC 2010 American Cancer Society.
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Breast -conserving therapy (BCT) has become the predominant surgical approach for most women with early stage
breast cancer.1,2 BCT compared with mastectomy has equivalent long-term survival,3-5 is associated with less disfigure-
ment, and has superior quality of life outcomes related to body image and sexual functioning.6-9 As a result, BCT has risen
steadily in the United States during the past couple of decades.
In contrast, the diffusion of BCT into clinical practice for elderly patients has been much slower and inconsistent.10
Previous research suggests that BCT has been underused in the elderly. Only 14% of elderly breast cancer patients were
treated with BCT in 1986, and this increased minimally to 15% in 1990.10 The most recent study from 1996 found that
less than half of elderly breast cancer patients undergo BCT with or without radiation.11 Reasons for the underuse of BCT
in the elderly are unclear. Low use of BCT has been correlated with rural healthcare settings,11-14 treatment received in the
southern and central United States,12,15 and low patient socioeconomic status.11,16 The influence of these nonclinical fac-
tors on the surgical treatment of breast cancer suggests that informed patient choice may not be fully optimized in this
population.
Because many of the largest studies evaluating BCT use are now more than a decade old, we examined the surgical
treatment of breast cancer in the elderly using a large national sample of Medicare patients. Our specific research questions
were: 1) What proportion of elderly US breast cancer patients receive BCT?; 2) How much geographical variation exists
in the use of BCT?; and 3)What nonclinical factors are correlated with the use of BCT?
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Patient information was obtained from a 100% sample of
MEDPAR (Medicare Provider Analysis and Review) and
outpatient files and a 20% sample of the carrier files from
the national Medicare database for the years 2003 to
2004. Data from the 2004 American Medical Association
were used to obtain surgeon-level information. The insti-
tutional review board of the University of Michigan
waived the requirement for informed consent.
Study Cohort
Our study cohort included only female Medicare benefi-
ciaries who were 68 years of age by January 1, 2003 and
who were entitled to Parts A and B of Medicare for all
of 2003 and 2004. This age limit was chosen so that
prevalent cases could be removed by excluding from the
cohort anyone with a breast cancer diagnosis or procedure
in the prior 3 years. We excluded the 6% to 18% (depend-
ing on year and region) of Medicare patients enrolled in
managed care plans, because these patients do not have
complete claims data.
Our sample included incident breast cancer cases
with or without radiation therapy and axillary lymph
node dissection. We identified incident breast cancer cases
in which surgical treatment was performed based on the
diagnostic and procedural codes in Medicare claims.
Distinguishing breast procedures performed for docu-
mented breast cancer versus diagnostic purposes required
a detailed algorithm that we adapted from Nattinger’s
published work because of its high sensitivity and positive
predictive value.17 In summary, patients were screened
as a possible case by having both of the following criteria:
1) a breast cancer procedure code for mastectomy or lum-
pectomy in the inpatient, outpatient, and/or carrier files;
and 2) any claim with a breast cancer diagnosis. Patients
were identified as a high likelihood case by meeting 1
of the following criteria: 1) radiation procedure code,
2) presence of 1 hospital stay with breast cancer as the
principle diagnosis in the calendar year after the procedure
date, or 3) 2 claims in either the carrier file or outpatient
file 7 days apart that indicated a breast cancer diagnosis in
the calendar year after the procedure date. Cases not
selected as a ‘‘high likelihood’’ case were included in the
cohort if there was >1 month of outpatient or carrier
claims with a breast cancer diagnosis. We excluded preva-
lent cases by removing any patient who had a breast cancer
diagnosis code or procedure code for lumpectomy or mas-
tectomy in the prior 3 years. We also excluded anyone
with a cancer diagnosis other than the breast (but exclud-




Our primary dependent variable of interest was
receipt of BCT. Women were considered to have received
BCT if they underwent a segmental mastectomy, lumpec-
tomy, quadrantectomy, tylectomy, wedge resection, exci-
sional biopsy, or partial mastectomy. The cohort included
women with or without lymph node dissection and with
or without radiation therapy. Patients were considered as
having a mastectomy if they had an International Classifi-
cation of Diseases, 9th Edition or Current Procedural
Terminology code for mastectomy, including simple,
subcutaneous, modified radical, and radical mastectomy.
Independent variables
The independent variables included 1) patient soci-
odemographic characteristics (age, race, composite socio-
economic status value, US state), 2) patient clinical factors
(Charlson score), and 3) surgeon characteristics (age and
sex). Patient age was categorized as <70, 70 to 75, 76 to
80, 81 to 85, and >85 years. We dichotomized patient
race into nonwhite and white. Patient comorbidity status
was dichotomized into 3 and >3 Charlson score, and
varying the cutoff to >2 did not significantly change the
results.
We constructed a summary measure of socio-
economic status for each US Zip code using data on
income, education, and occupation from the 2000 US
Census, which was then linked to the patient’s ZIP code
of residence from the Medicare files. The individual
variables chosen and methods for calculating the summary
measure were based on previously developed methods.18,19
Patients were sorted according to summary socioeconomic
status score and then grouped into quintiles ranging from 1
(lowest) to 5 (highest).
Surgeon-level factors were obtained from the
American Medical Association file. Surgeon age was
grouped as <40, 40 to 49, 50 to 59, and >59 years. Sur-
geon sex was dichotomized (male, female).
Statistical Analysis
We first described receipt of mastectomy and BCT across
all patients and surgeon-level factors. Pearson chi-square
was used for the bivariate analyses between outcomes and
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categorical independent variables. We also described the
adjusted proportion of breast cancer patients treated with
BCT by US state. Rates were adjusted for patient-level
factors (age, race, comorbidity score, and socioeconomic
status) and surgeon-level factors (age and sex). We
excluded from the analyses states with10 procedures for
reporting to avoid unstable estimates of regional variation.
We also excluded 157 cases for which we were unable to
match surgeon-level to patient-level data.
We performed a multivariate logistic regression to
evaluate patient-level and surgeon-level factors associated
with receipt of BCT. Second order interactions were
included in our regression based on our conceptual
model. The Wald test and the likelihood ratio test were
used to test the significance of individual predictive varia-
bles. The final multivariate model included those interac-
tion terms significant at P < .05. All modeling reports
odds ratios (ORs) and 95% confidence intervals (CIs).
Analyses were performed with SAS version 9.2.
RESULTS
Our sample included 20,032 breast cancer patients
(18.2% with mastectomy and 81.8% with BCT). Of this
sample, 18.9% of mastectomy-treated patients received
radiation, and 49.5% of BCT patients received radiation.
Table 1 displays the proportion of patients receiving BCT
across the United States, adjusted for patient-level and
surgeon-level factors. Minimal regional variation was
found, with BCT use ranging from 74.2% in Utah to
84.0% in New Mexico. Other high-use states included
Arizona (83.0%), New Hampshire (82.7%), Massachu-
setts (82.7%), and Montana (82.1%). Among the high-
use regions, there were 24 states that were within 4% of
each other. Comparatively low-use states included Missis-
sippi (75.3%), Alabama (75.7%), South Dakota (77.0%),
andWisconsin (77.0%).
Table 2 describes receipt of BCT across patient clin-
ical and demographic factors. Older, compared with
younger patients, were significantly less likely to receive
BCT. For example, 72.9% of patients >85 years of age
received BCT compared with 85.9% of patients <70
years of age (OR, 0.50; 95% CI, 0.42-0.59). Presence of
multiple comorbidities was associated with low use of
BCT. Only 61.9% of those with a Charlson score >3
received BCT, compared with 87.4% of those with a
Charlson score 3 (OR, 0.26; 95% CI, 0.24-0.28). In
addition, patient socioeconomic status was associated
with surgical treatment. Only 78.2% of patients in the
lowest socioeconomic status quintile received BCT, com-
pared with 86.3% of those in the highest quintile (OR,
0.60; 95% CI, 0.52-0.68). Patient race was not statisti-
cally associated with BCT use.
The sample included 9893 surgeons (8325 men and
1568 women). The mean surgeon age was 51.9 years for
men and 46.0 years for women. Approximately 20% of
the surgeons were <40 years of age, 1=3 were in their for-
ties, 1=3 were in the fifties, and 20% were60 years of age.
The average number of patients per surgeon was 2.44 for
female surgeons and 1.89 for male surgeons. Figure 1
displays the interaction of surgeon age and sex with the
proportion of patients receiving BCT, controlling for
patient age, race, Charlson score, and socioeconomic
status. BCT use among surgeons was relatively similar.
However, compared with surgeons <40 years of age, the
proportion of patients receiving BCT was significantly
lower among male versus female surgeons 40 to 49 years
of age (80.3% vs 86.0%: OR, 0.72; 95% CI, 0.54-0.96)
and among those60 years of age (80.6% vs 91.3%: OR,
0.36; 95%CI, 0.17-0.76).
DISCUSSION
In this large population-based study using Medicare data
from 2003 and 2004, we found that the overall use of
BCT in the elderly was high (82%) and varied minimally
from 74% to 84% across the United States. However,
certain nonclinical factors were significantly associated
with the use of BCT. Elderly patients who were more
socioeconomically disadvantaged were significantly less
likely to receive BCT. Surgeon characteristics were
modestly associated with the use of BCT, with older
female surgeons associated with the highest use.
These data suggest that BCT is now widely adopted
for elderly breast cancer patients in the United States.
Greater than 80% of elderly breast cancer patients in our
sample received BCT, which is considerably higher than
earlier reports of BCT use ranging from 12%-24% in the
1980s12,20 to 15%-43% in the 1990s.10,21 Geographical
variations in the surgical care of elderly breast cancer
patients also appear reduced. Our study found surpris-
ingly little difference in the adjusted rates of BCT use
across the United States, with only a 10% difference
between the highest and lowest use state. In comparison,
rates of BCT in the 1980s ranged from 3.5% to 21.2%
across the United States.12 Even as recently as 1995, the
use of mastectomy in the elderly was found to vary by 4.7-
fold across hospital referral regions, from 0.91 per 1000
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Medicare enrollees in Ormond Beach, Florida, to 4.26
per 1000 Medicare enrollees in Neenah, Wisconsin.22
Reasons for the increased adoption of BCT in the surgical
treatment of elderly breast cancer patients are unclear but
can include patient preference, surgeon bias, and dissemi-
nation of knowledge. Furthermore, the increased use of
BCT in the elderly may reflect accumulating knowledge
that antiestrogen treatment provides similar survival and
local control as radiation.23 The reduced geographical
variation in the surgical treatment of elderly breast cancer
patients suggests that the clinical uncertainty of BCT has
diminished among patients and physicians.
Table 1. The Use of Breast-Conserving Therapy by US State Among Medicare Enrollees With Breast
Cancer During 2003 to 2004











Alabama 270 78.0 81.3 75.7
Arizona 215 80.8 83.2 83.0
Arkansas 169 71.6 79.9 80.0
California 1119 81.9 83.1 81.9
Colorado 167 80.3 83.3 81.3
Connecticut 297 91.4 83.2 79.9
Florida 1273 84.8 82.1 80.2
Georgia 406 76.7 82.3 80.2
Idaho 72 76.6 81.9 81.1
Illinois 825 84.4 82.3 81.3
Indiana 395 80.6 81.4 79.3
Iowa 241 77.7 81.5 77.4
Kansas 205 76.8 80.9 78.5
Kentucky 249 78.8 81.0 80.0
Louisiana 263 83.5 79.3 78.5
Maine 111 85.4 82.2 81.1
Maryland 336 84.4 82.1 78.4
Massachusetts 433 91.5 83.9 82.7
Michigan 734 86.9 82.6 80.3
Minnesota 275 76.8 82.3 79.0
Mississippi 169 70.1 79.5 75.3
Missouri 374 80.1 80.4 78.3
Montana 73 72.3 82.9 82.1
Nebraska 116 76.3 80.8 80.7
Nevada 68 76.4 81.1 79.2
New Hampshire 89 82.4 84.2 82.7
New Jersey 581 86.7 82.1 81.0
New Mexico 84 88.4 83.8 84.0
New York 1127 86.1 81.5 78.9
North Carolina 514 76.4 81.9 80.0
North Dakota 48 69.6 81.6 81.7
Ohio 716 82.8 81.1 80.3
Oklahoma 215 79.3 81.3 80.1
Oregon 167 83.1 83.9 80.7
Pennsylvania 787 83.0 80.3 78.8
South Carolina 278 81.5 81.1 77.2
South Dakota 50 74.6 80.7 77.0
Tennessee 320 77.5 80.3 79.2
Texas 868 75.4 81.1 79.4
Utah 82 77.4 84.2 74.2
Virginia 441 85.1 82.4 80.9
Washington 328 80.6 82.3 80.0
Wisconsin 133 82.6 80.9 77.0
Wyoming 400 78.9 81.1 79.1
BCT indicates breast-conserving therapy.
a Patient-level factors controlled for in the analyses include age, race, Charlson score, and socioeconomic status; sur-
geon-level factors that were controlled for include age and sex.
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The association of advanced patient age and multi-
ple comorbidities with low use of BCT is not unexpected.
The use of mastectomy eliminates the need for postsurgi-
cal radiation therapy. Avoidance of radiation has benefits
for the elderly and for those with a high health burden,
especially those dependent on others for transportation.
In addition, elderly compared with younger women may
not have the same body image needs driving the choice
for BCT.
Our results support Nattinger’s previous finding
that socioeconomic status, not race, is a significant corre-
late of BCT use.11 The association between patient socio-
economic status and surgical breast cancer care has been
well documented over the past 15 years14,20,24-29 and
raises concern that disadvantaged women are facing
knowledge or financial barriers that influence their treat-
ment decision. Potential reasons for relatively lower use of
BCT include poor communication with surgeons,30
inadequate information about treatment options,31,32
difficulty with the decision-making process,30,33,34 and/or
financial barriers related to radiation, transportation, and
time off work.20,35
Although we found differences in the use of BCT by
surgeon factors, the clinical magnitude of these differences
was relatively small. Reasons for sex-based differences in
treatment can not be ascertained by our study. However,
previous work by Katz et al has shown that surgeon prefer-
ences for surgery are strongly associated with perceptions
about the relative treatment benefits related to quality of
life.36 Female surgeons, however, appear to be less
inclined to favor 1 procedure over the other and less likely
to view BCT as superior to mastectomy with regard to
quality of life outcomes.36 It is not surprising to find that
male and female surgeons conceptualize the loss of a
breast differently. The preferences of providers are at risk
for being communicated to the patient. Fortunately, our
study found minimal surgeon effect on BCT use, which
suggests that surgeons across the United States minimize
any personal bias in patients’ surgical treatment decision
making.
Limitations
Our findings should be interpreted in the context of some
limitations. We did not have breast cancer stage informa-
tion. However, we did find markedly increased rates
of BCT in the elderly using the same population and
methods as previous studies.10,12 Therefore, stage should
not be a significant confounder. The association between
socioeconomic status and BCT use could be confounded
by disease stage. However, a similar trend was found by














68-70 1511 (85.9%) 1.00 —
70-74 4948 (85.5%) 1.01 0.86-1.19
75-79 4424 (83.1%) 0.85 0.73-1.00
80-84 2972 (78.1%) 0.62 0.53-0.73
>85 1720 (72.9%) 0.50 0.42-0.59
Patient race
Nonwhite 1469 (79.8%) 1.00 —
White 14,106 (82.1%) 1.01 0.87-1.19
Charlson score
<3 13,989 (87.4%) 1.00 —
>3 2343 (61.9) 0.26 0.24-0.28
Patient SES
5th quintile (highest) 3301 (86.3%) 1.00 —
4th quintile 3200 (83.8%) 0.83 0.73-0.95
3rd quintile 3062 (80.1%) 0.65 0.58-0.75
2nd quintile 3069 (80.7%) 0.69 0.60-0.78
1st quintile (lowest) 2943 (78.2%) 0.60 0.52-0.68
BCT indicates breast-conserving therapy; OR, odds ratio; CI, confidence
interval; SES, socioeconomic status.
a Logistic regression modeling the probability of a BCT versus a mastec-
tomy. We omitted 157 cases due to the inability to link surgeons to
patients. The model controlled for surgeon age and sex.
Figure 1. Adjusted proportion and odds ratios of receipt of
breast-conserving therapy (BCT) are shown by surgeon age
and sex, controlling for patient age, race, Charlson score, and
socioeconomic status. The reference group is male surgeons
<40 years of age. *Statistically significant at P < .05.
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Gilligan et al using Medicare-Surveillance, Epidemiology,
and End Results (SEER) data that controlled for disease
stage.11 We also found that the stage of breast cancer did
not vary significantly across SEER-Medicare regions in
the same time period after adjusting for patient socio-
demographic factors and hospital volume. Therefore, we
have no reason to believe that stage would vary across US
states and be a significant confounder regarding geograph-
ical variations in BCT use. Stage of disease could also vary
across surgeons; however, we have no reason to believe
that disease stage would systematically vary by surgeon
age and sex. There are also broader trends toward earlier
diagnosis of breast cancer that could increase rates of
BCT. However, the magnitude of the increase in BCT use
that we found is too large to be explained by earlier cancer
diagnosis. We used methods described by Nattinger et al
to identify incident breast cancer patients in Medicare,
which have a sensitivity of 80%, specificity of 99.9%, and
positive predictive value of 93%.17 We have no reason to
suspect that any misclassification error would distort our
findings. It should also be noted that the identification of
surgeons in Medicare using unique physician identi-
fication numbers can be difficult and can potentially
inappropriately aggregate data. In addition, the percent-
age of women with BCT identified as having radiation is
lower than would typically be expected. This finding may
be an artifact of the data files we used to identify radiation
(carrier file), and is among the reasons we used addition
definitional criteria to identify our sample. We were
also dependent on US Census data to estimate patient
socioeconomic status. However, any misclassification
should be nondifferential and would minimize between-
group variation.
Implications
Our findings have important implications for patient care
and policy. Physicians, patients, and women’s health
policy advocates have spent considerable time and energy
toward ensuring breast cancer patients’ access to BCT. The
high use of BCT and the decreased geographical variation
in use suggests that evidence-based research has diffused
into clinical practice for elderly breast cancer patients.
However, the influence of socioeconomic status on
surgical care is concerning. Individual patients should be
treated with a strategy that is best for them. This can be
facilitated through shared medical decision making. One
approach is to develop and deploy decision tools that
physicians can use to educate patients about the risks, ben-
efits, and long-term outcomes of all of the surgical options
(breast conservation, mastectomy alone, and mastectomy
with reconstruction). Decision tools may be particularly
beneficial to patients of lower socioeconomic status and
those overwhelmed by the cancer diagnosis or who may
be intimidated by the healthcare system. Decision tools
can improve patients’ knowledge of surgical options in an
unbiased, less pressured environment and have been asso-
ciated with improved decisional quality for breast cancer
care.37 Decision tools can also be used to tailor interven-
tions to match patient values.38 Ultimately, the true mea-
sure of quality relies not on rates of BCT but the extent to
which patients are adequately informed of treatment
options and treatment decisions reflect patients’ personal
values.
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